CAR-T cells vs bispecific monoclonal antibodies in lymphoma therapy
Among the hot topics of the sixteenth ICML edition in Lugano is that relating to the long-term results of the use of CAR-T cells. The efficacy of the therapy is confirmed but the advent of bispecific monoclonal antibodies seems to provide a less toxic and less complex tool. The first results indicate that even patients who have previously been treated with CAR-T cells, in the event of a relapse, can respond again if they are treated with the new therapeutic modality.
Among the hot topics of the sixteenth ICML edition in Lugano is that relating to the long-term results of the use of CAR-T cells. The efficacy of the therapy is confirmed but the advent of bispecific monoclonal antibodies seems to provide a less toxic and less complex tool. The first results indicate that even patients who have previously been treated with CAR-T cells, in the event of a relapse, can respond again if they are treated with the new therapeutic modality.
ICML 16 - Lugano 2021 Virtual Edition
ICML 2021: vantaggi e svantaggi della modalità congressuale virtuale
it
Prof. Franco Cavalli
I temi focali trattati a ICML 2021
it
Prof. Franco Cavalli
Architecture of research in Lymphoma monitoring
en
Ash A. Alizadeh
Immune environment in the malignancy of Non-Hodgkin Lymphoma
en
Stephen M. Ansell
CAR-T cells vs bispecific monoclonal antibodies in lymphoma therapy
it
Prof. Franco Cavalli
Follicular Lymphoma: main vulnerabilities
en
Elías Campo
New developments in Lymphoma radiotherapy
en
Lena Specht
Lymphoid malignancy, interactions of the new drugs in real life
en
Anastasios Stathis